KYMR — Expected Completion of Phase 2 Study of SAR444656
Jul 17, 2026, 4:00:00 AM UTC
Summary
Sanofi's Phase 2 clinical trial of SAR444656 for treating moderate to severe Hidradenitis Suppurativa is expected to complete on July 17, 2026. The study, which is currently recruiting, aims to assess the efficacy, safety, pharmacokinetics, and biological effects of SAR444656 in adult participants aged 18 to 70 years. The trial will involve a total duration of up to 24 weeks, including treatment and follow-up phases, and aims to enroll 156 participants. This research could have significant implications for investors monitoring developments in therapies for Hidradenitis Suppurativa, an inflammatory skin condition.
Company
KYMERA THERAPEUTICS INC (KYMR)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
Similar Events
Expected Completion of Phase 2 Study of SAR444656 in Atopic Dermatitis
Sanofi's Phase 2 study of SAR444656 for moderate to severe atopic dermatitis is expected to complete on August 18, 2026. The study involves 200 adult participants who are inadequately controlled by topical treatments or for whom such treatments are inadvisable. They will be randomized to receive either SAR444656 or a placebo over a 24-week period. Given its design as a multicenter, double-blind, placebo-controlled trial, the outcomes could provide significant insights into the drug's efficacy and safety, potentially affecting future treatment protocols and market dynamics for atopic dermatitis therapies.
Clinical Trial CompletionExpected Completion of Phase 2 Study of BA3021
BioAtla, Inc. is conducting a multi-center, open-label Phase 2 study of BA3021 to evaluate its efficacy and safety in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The expected completion date for this clinical trial is December 1, 2026, with an enrollment count of 290 patients. The study is currently in the recruiting phase and will assess BA3021 both as a monotherapy and in combination therapy. This trial's outcome could potentially impact treatment options for this patient population, relevant for investors assessing BioAtla's pipeline developments.
Clinical Trial CompletionExpected Trial Completion for SAR442257 Clinical Study
Sanofi expects to complete the first-in-human clinical study of its investigational drug SAR442257, targeting relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory non-Hodgkin lymphoma (RR-NHL), on March 17, 2026. The trial, which is currently active but not recruiting, began on July 24, 2020, with an enrollment count of 47 participants. The study is designed to assess the pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy of SAR442257, with individual participant study durations ranging from 2 to 16 months. The completion of this trial could provide critical data on this novel therapeutic agent for investors focused on oncology.
Clinical Trial CompletionExpected Completion of Phase 2A Clinical Trial for RAP-219
Rapport Therapeutics Inc. is expected to complete its Phase 2A clinical trial of RAP-219 for refractory focal epilepsy on June 1, 2025. This proof-of-concept study aims to evaluate the drug's efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic relationship in approximately 20 adult participants treated with the RNS® system. The trial is currently recruiting patients, with the trial's start date set for October 10, 2024. The completion of this trial could provide pivotal data for the future development of RAP-219 in addressing refractory focal epilepsy, a condition with significant unmet medical needs.
clinical trial completion